



# ASX Announcement

**For immediate release**

17 August 2016

## **CSL ANNOUNCES CHANGES TO THE BOARD**

**CSL Limited (ASX:CSL; USOTC:CSLLY)** – CSL today announced that Dr Tadataka “Tachi” Yamada KBE has been appointed a Director effective from 1 September 2016. The Company also announced that Mr John Akehurst, has indicated his intention to retire from the CSL Board of Directors at the conclusion of the Company’s Annual General Meeting on 12 October 2016.

Dr Yamada is a US citizen, resident in Seattle, Washington. He is presently a Venture Partner at Frazier Healthcare Partners, a leading provider of growth capital to healthcare companies, a position that he has held since 2015. Prior to this, he was the Chief Medical and Scientific Officer at Takeda Pharmaceuticals, as well as a member of the Board. Dr Yamada has held a range of leadership positions in the health sector, including as President of the Bill & Melinda Gates Foundation Global Health Program and Chairman of Research and Development at GlaxoSmithKline. He currently serves as a director of Agilent Technologies, Inc. and the Clinton Health Access Initiative and a member of the Council of the National Academy of Medicine. Dr Yamada is also a Fellow of the Imperial College of Medicine, a Master of the American College of Physicians and a Fellow of the Royal College of Physicians.

CSL’s Chairman, Professor John Shine AO said “I am delighted that we have been able to appoint a person with such deep industry knowledge and extensive international experience. I am certain that his knowledge and insights will be of benefit to CSL as we enter the next exciting phase in the Company’s future.”

Mr Akehurst has been a Director of the Company since April 2004. He has been a Member of CSL’s Human Resources and Remuneration Committee since that time, and has been Chairman of that Committee since October 2011. During this time, he has been a strong supporter of the Company’s strategy to seek out opportunities to grow and expand internationally which have helped transform CSL into the global speciality biopharmaceutical company that it is today.

Professor Shine said “John has been a valuable contributor to the Board over an extended period, especially in his capacity as a member of the Human Resources and Remuneration Committee, which he has chaired since October



# ASX Announcement

**For immediate release**

Page 2

17 August 2016

2011. He has also taken a keen interest in championing Health and Safety within CSL, an area which has seen improved performance during his tenure. I would like to express my sincere thanks for his outstanding service as a director.”

**For more information about CSL Limited, visit [www.csl.com.au](http://www.csl.com.au)**

## **Media Contact**

Ms Jemimah Pentland  
Head of Communications, Asia Pacific  
Phone: 61 3 9389 3473  
Email: [jemimah.pentland@csl.com.au](mailto:jemimah.pentland@csl.com.au)

## **Investor Contact**

Mark Dehring  
Head of Investor Relations  
Phone: 61 3 9389 3417  
Email: [mark.dehring@csl.com.au](mailto:mark.dehring@csl.com.au)